Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted to SN‑38, which binds to the DNA‑topoisomerase I complex. By stabilizing this complex, it prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and tumor cell death.

The dose of Irinotecan is individualized by the prescribing oncologist based on factors such as body surface area, disease stage, prior therapies, and patient tolerance. Specific dosing regimens are determined by the treating physician and are not standardized in public information.

Safety of Irinotecan during pregnancy or lactation has not been established. It is generally avoided unless the potential benefit to the mother outweighs the possible risk to the fetus or infant. Consultation with a specialist is essential before use in these populations.

To order Irinotecan Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as oxaliplatin (a platinum compound) or fluoropyrimidines. Compared with topotecan, another topoisomerase I inhibitor, Irinotecan is the standard choice for colorectal cancer, offering established efficacy in combination regimens like FOLFIRI.

Irinotecan should be stored at 2‑8 °C, protected from light, and must not be frozen. The product should be kept in its original packaging to maintain stability, and handling should follow aseptic techniques appropriate for intravenous chemotherapy agents.

Irinotecan is administered by intravenous infusion, typically over 30 to 90 minutes depending on the protocol. It is given in cycles, often every two weeks, as part of combination chemotherapy regimens. Administration is performed by qualified healthcare professionals in a clinical setting.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea that can lead to dehydration, and intestinal perforation. Prompt recognition and medical intervention are critical; patients should be monitored closely for signs of infection, severe gastrointestinal symptoms, and abdominal pain.

Irinotecan should be avoided in patients with known hypersensitivity to the drug or its components, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment. Caution is also advised for individuals with a history of gastrointestinal disorders that could predispose to perforation.